Mucosal formulation
US8703179B2 · kind B2 · utility
9Cited by
23References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2006 |
| Grant date | Apr 22, 2014 |
| Priority date | — |
| Expiry date | Jan 19, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the aqueous phase (i.e., “amphipathic” lipids). When placed in an aqueous medium (e.g., vaginal fluid), the phospholipids form liposomes or other small lipid vesicles (e.g., micelles) that may then be used to deliver pharmaceutical agents into a living organism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.